A recent pre-clinical study provided evidence that co-treatment of breast cancer cells with AEW541 (a selective IGF1R inhibitor) along with gemcitabine (a chemotherapeutic drug) improved the treatment efficiency (31). This evidence concerns the gene IGF1R and breast cancer.